Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q2 2024 (June 30)10holders −1
1new positions
2sold out
$8.86avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, down 1 from Q1 2024. 1 opened new positions and 2 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($4.4M), Ra Capital Management, L.P. ($2.9M) and Affinity Asset Advisors, LLC ($1.9M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $87K |
| Exits | 2 | $1.7M |
All 13F filers, Q1 2024 → Q2 2024: 10,000 shares bought and 152,339 shares sold, net −142,339 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $4.4M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $2.9M |
| Affinity Asset Advisors, LLC | — | No change | 202,599 | $1.9M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 100,000 | $872K |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $809K |
| HRT Financial LP | — | No change | 30,321 | $286K |
| Laurion Capital Management LP | — | No change | 16,666 | $145K |
| Vestcor Inc | — | No change | 9,632 | $91K |
| TFC Financial Management, Inc. | — | New | 10,000 | $87K |
| CIBC Private Wealth Group LLC | — | No change | 1,000 | $10K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.